Search published articles
Showing 2 results for Chronic Myeloid Leukemia
Volume 10, Issue 0 (8-2008)
Abstract
Objective: Chronic Myeloid Leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells which results in increase of myeloid cells, erythroid cells and platelets in the peripheral blood and hyperplasia in bone marrow. Investigations have shown different types of BCR- ABL variants in these patients. In Iran only 3 types of these variants have been identified because most of the clinical laboratories usually use only few sets of primers which can not detect all types of the variants simultaneously. In this study we developed a method with which all types of variants in chronic Myeloid leukemia patients can be recognized.
Materials and Methods: blood samples from 100 persons who were under treatment or diagnosis for CML were received from Clinical laboratory. RNA was extracted from 600 µl of each sample using Roche Commercial kit and converted to cDNA by reverse transcriptase enzyme the cDNAs were analyzed for BCR- ABL variants using two sets of primers. All samples were also studied by RT- Multiplex Nested PCR method.
Results: RT-Multiplex PCR could detect BCR-ABL in all samples which were positive for these Fusion Gene mRNA. From 100 collected samples 46 percent were positive and 54 percent were negative by RT-Multiplex PCR method and 44 percent were positive and 56 percent were negative by RT-Multiplex Nested PCR method.
Conclusion: By using one step PCR we detected more variants of BCR- ABL in one tube at shorter time and lower cost. This method showed 100 percent specificity and can further be improved by taking more samples and also real time PCR for quantitative analysis.
F. Asgari, R. Mahinpour , N. Haghighipour , L. Moradi,
Volume 10, Issue 2 (7-2019)
Abstract
Chronic myeloid leukemia (CML) is a malignant blood disease with a particular chromosomal aberration and it is known as a common form of leukemia. Chromene family exhibit strong anti-cancer effects. Therefore, in this study, the effect of two derivatives of dihydro-pyrano [2, 3-g] chromene family is investigated on cell toxicity and apoptosis induction in K562 cancer cells and compared them with Peripheral Blood Mononuclear (PBMC) normal cells. The K562 cell line was cultured in the presence of the mentioned chromene derivatives at a concentration of 40-200µM for 24-72 hours. The effect of these compounds on growth and viability of K562 cell line and PBMC cells were studied via MTT assay and apoptosis induction was investigated by flow cytometry. The results showed that these chromene derivatives inhibit K562 cell line growth. Moreover, increasing the chromene concentration and the time of exposure to it increase the cell toxicity. Among these compounds, 4-No2pgC was known as a compound with high toxicity (IC50=129±2.75) and 4-MePgC recognized as a compound with low toxicity (IC50=214±3.42) after 72 hours exposure to the K562 cell line. Furthermore, the results of flow cytometry demonstrated the effect of apoptosis induction of these compounds on the K562 cell line. According to the obtained results from this research, chromene derivatives can induce apoptosis in the K562 cell line and these compounds have a less toxic effect on normal cells than cancer cells. In conclusion, these derivatives can be considered as a proper candidate for the treatment of leukemia.
